That's a wrap for #ASH22! Thank you to all MSK MSK Department of Medicine faculty who shared their research with the #oncology community. ASH #leusm #lymsm #mmsm You can follow our blood cancer experts to learn about the latest research: bit.ly/3HxCx5A

In a Comment now published online, Karthik Nath, Bruno Costa & Sham Mailankody Memorial Sloan Kettering Cancer Center Weill Cornell Medicine Icahn School of Medicine at Mount Sinai discuss therapies targeting GPRC5D in #MultipleMyeloma nature.com/articles/s4157…

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy ashpublications.org/blood/article-…

Deadline approaching — Don't miss the opportunity to share your work at the 3rd International Symposium on #Toxicities after Transplantation & #CellularTherapy #MSKToxTCT. Top 5 awards receive complimentary registration! Submit your #abstract by March 31: bit.ly/MSKToxTCT

Important Reminder — Early rates expire this Friday, 3/17, for the #MSKToxTCT Symposium. Join experts from around the 🌍 for this exciting program focused on toxicities of #HCT & #CellularTherapies w/ ample networking. Register: bit.ly/MSKToxTCT Michael Scordo Sergio Giralt

Current view and typical view from Memorial Sloan Kettering Cancer Center Koch Center into Queens.

The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bis... sciencedirect.com/science/articl… #CART #bmtsm #CARTcell #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy ASTCT Chimeric Antigen Receptor T-Cell (CAR-T) & Gene Rx

Prophylactic use of anakinra, an IL-1 receptor inhibitor, reduced severe #neurotoxicity incidence in patients with r/r #lymphoma treated with anti-CD19 #CARTcells #immunotherapy Jae Park @karthik_nath17 @Michel_Sadelain Memorial Sloan Kettering Cancer Center MSK Department of Medicine nature.com/articles/s4159…

Happy to see our paper published on the benefit of IL-1 inhibition to prevent neurotoxicity a/w CD19 CAR T cell therapy! Great collaboration with fantastic faculties and research team at MSK CTS. Continuing our effort to make CAR T cell therapy safer!

An MSK team led by Jae Park found that giving a drug called anakinra patients undergoing #CARTcelltherapy reduced severe neurotoxicity from a rate of 28%–38% usually seen with standard anti-CD19 CAR T therapy to only 9.7%. Read more here: mskcc.org/news/msk-resea…

Five years ago, I chose Memorial Sloan Kettering Cancer Center in New York for lifesaving care from a team of oncologists and surgeons. In 2022, I was honoured to cut the ribbon with distinguished guests at MSK’s India centre in Chennai. Today, MSK serves India via a remote #secondopinion program, and

MSK's Jae Park and colleagues share good news on #hairycellleukemia

Dive into the extensive 2nd edition Volume 2 handbook, a comprehensive 800-page guide featuring 61 pragmatic and actionable insights from globally acclaimed experts in Hematology and Bone Marrow Transplantation (BMT). Uncover the latest advancements and practical wisdom!

.Memorial Sloan Kettering Cancer Center experts presented research related to managing and reducing treatment-related toxicities at #ASH23. Read through some of top highlights from Cy R. Wilkins, Jae Park, Karthik Nath, Alina Markova, MD, and Roni Shouval: bit.ly/47T0ONP (ASH)

One of our top ten articles this month Karthik Nath et al in Transplantation and Cellular Therapy Journal on Reduced Intensity Compared to Non-myeloablative Conditioning in Patients with Non-Hodgkin Lymphoma undergoing Allo-HSCT stemcellevidence.com/alerts/article… #BMT #lymsm #StemCellEvidence

Interesting findings brilliantly presented by Karthik Nath at #EBMT24. Use of a young MUD is associated with superior disease control and higher DFS compared to older MSDs, and may be preferred when available, in patients aged ≥50-years receiving CNI-based GvHD prophylaxis.

Pleasure to speak with Karthik Nath (Memorial Sloan Kettering Cancer Center) at #EBMT24, who discussed the benefit of prioritizing young matched unrelated donors in alloSCT for patients over the age of 50. Visit VJHemOnc.com to explore some of our EBMT content! #BMTsm The EBMT

⁦Karthik Nath⁩ giving a fine presentation on our work comparing older siblings to younger matched URDs when PTCy is used. Younger URDs improved disease free survival compared to older siblings. Manuscript coming!

Infectious complications with BCMA-directed therapies in multiple myeloma; N=147 (CAR-T 92, bispecifics 55). Incidence of severe infections was significantly higher with bispecifics than CAR-T cells #mmsm #bmtsm Blood Cancer Journal Karthik Nath Zainab Shahid MD, FACP, FIDSA 🇺🇸🇵🇰 nature.com/articles/s4140…

Check out our comparative analysis of infectious complications with BCMA-directed therapies for RRMM, just published in Blood Cancer Journal: nature.com/articles/s4140… N=256 (92 CAR-T, 55 BsAb, 109 ADC). Grade ≥3 infection rates were higher with BsAbs (40%) than CAR-T (26%) or